← Browse by Condition
Medical Condition

lung non small cell carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for lung non small cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — lung non small cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for lung non small cell carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for lung non small cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung non small cell carcinoma?
lung non small cell carcinoma research spans Phase 1 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung non small cell carcinoma clinical trial?
Eligibility criteria for lung non small cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
M.D. Anderson Cancer Center 1 trial
University of Michigan Rogel Cancer Center 1 trial
National Cancer Institute (NCI) 1 trial

Recruiting Clinical Trials

NCT04913311
Recruiting
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
Enrollment
150 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06225427 Phase 1
Recruiting
Gilteritinib for the Treatment of ALK NSCLC
Enrollment
30 pts
Location
United States
Sponsor
University of Michigan Rogel C...
View Trial →
NCT06498635 Phase 3
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Enrollment
306 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →

Related Conditions

stage iv lung cancer ajcc v8 (1) stage ii lung cancer ajcc v8 (1) stage iiia lung cancer ajcc v8 (1) stage iiib lung cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology